Clinical Trials
2.6k
Trial Phases
6 Phases
Drug Approvals
92
Clinical Trials
Distribution across different clinical trial phases (2077 trials with phase data)• Click on a phase to view related trials
A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the Blood
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT07211425
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Conditions
- Familial Pulmonary FibrosisInterstitial Lung AbnormalitiesInterstitial Lung Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT07201922
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇫🇷HOP Louis Pradel, Bron, France
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 400
- Registration Number
- NCT07195695
- Locations
- 🇺🇸
Community Cancer Trials of Utah, Ogden, Utah, United States
🇺🇸Premier Cancer Care, Fresno, California, United States
🇺🇸University of California Los Angeles, Santa Monica, California, United States
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 46
- Registration Number
- NCT07176975
- Locations
- 🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan
A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood
- Conditions
- Healthy
- Interventions
- Drug: vicadrostat / empagliflozin combination 1Drug: vicadrostat / empagliflozin 2
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT07133399
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 449
- Next
News
Boehringer Ingelheim Acquires First-in-Class Oncology Asset from Accent Therapeutics Targeting High ISG Expression Tumors
Boehringer Ingelheim has acquired a potentially first-in-class preclinical small molecule program from Accent Therapeutics targeting tumors with high interferon-stimulated gene (ISG) expression.
Qurient and Synaffix Partner to Develop First-in-Class CDK7 Dual-Payload ADC for Refractory Cancers
Qurient has signed a licensing agreement with Synaffix to develop a dual-payload ADC combining Qurient's CDK7 inhibitor mocaciclib with Synaffix's exatecan-based technology.
TegMine Therapeutics Partners with Boehringer Ingelheim to Develop Next-Generation ADCs Using Novel 2-Factor Antibody System
TegMine Therapeutics has entered a strategic research collaboration with Boehringer Ingelheim to develop safer, more selective antibody-drug conjugates using TegMine's proprietary 2-Factor Antibody System.
Roche Acquires 89bio for $3.5 Billion to Strengthen MASH Treatment Pipeline
Roche announced a definitive merger agreement to acquire 89bio for $14.50 per share in cash plus contingent value rights, totaling up to $3.5 billion.
UPC Court of Appeal Grants First Pharmaceutical Preliminary Injunction, Setting New Standard for Generic Drug Market Entry
The Unified Patent Court's Court of Appeal granted its first preliminary injunction in the pharmaceutical sector, blocking Zentiva from launching generic versions of Boehringer Ingelheim's Ofev across 17 European territories.
FDA Accepts First Non-Invasive Surrogate Endpoint for MASH Clinical Trials
The FDA has accepted Echosens' Letter of Intent to qualify liver stiffness measurement by FibroScan® as the first non-invasive surrogate endpoint for MASH clinical trials.
DAPA ACT HF-TIMI 68 Trial Shows Promise for In-Hospital SGLT2 Inhibitor Initiation Despite Missing Primary Endpoint
The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
Boehringer Ingelheim Partners with AnGes for HGF Gene Therapy Manufacturing Ahead of FDA Filing
Boehringer Ingelheim has signed a contract development and manufacturing agreement with AnGes for the drug substance of their investigational hepatocyte growth factor gene therapy targeting peripheral arterial disease.
Molecular Partners Appoints Martin Steegmaier as Chief Scientific Officer to Advance DARPin Therapeutics Pipeline
Molecular Partners has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer effective October 1, 2025, bringing extensive oncology drug development experience from senior roles at Roche, MorphoSys, Boehringer Ingelberg, and SOTIO Biotech.